PCAC review · February 2027 panel
FDA's Pharmacy Compounding Advisory Committee scheduled to review the second cohort of peptides removed from Category 2 in April 2026. Panel votes whether to add each to the official 503A bulks list.
10-amino acid C-terminal fragment of KISS1 gene product. Master regulator upstream of GnRH — stimulates LH/FSH release with high physiological precision.
Imperial College London (Dhillo lab) clinical research uses kisspeptin in hypothalamic amenorrhea and IVF cycle optimization. Pulsatile delivery mimics endogenous GnRH biology better than HCG. Not commercialized; clinical access is research-protocol-only.
Not commercially available. Anything sold as 'kisspeptin' to retail biohackers should be treated with extreme skepticism. Real protocols use IV pulse infusions, not subcutaneous self-administration.
Per-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.
External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.
Pre-filled with this compound's published dose range: research-only · research-protocol IV pulses
Calculator is a discussion tool. Verify reconstitution + dosing with a qualified provider. Stack is not a prescription source. Use sterile technique and inspect every vial.
Expected reclassification — PCAC review Feb 2027
FDA's Pharmacy Compounding Advisory Committee scheduled to review the second cohort of peptides removed from Category 2 in April 2026. Panel votes whether to add each to the official 503A bulks list.